Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-09-13
1996-10-22
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514114, 514555, 514665, A61K 3166
Patent
active
055676863
ABSTRACT:
A method and pharmaceutical for protecting against mutational damage in mammalian cells, irrespective of the nature of the mutagenic event or source of radiational or chemical insult or the like.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
"A Survey of Compounds From the Antiradiation Drug Development Program of the U.S. Army Medical Research and Development Command," Walter Reed Army Institute of Research, Washington, DC, Sep. 1979.
Corn, B. W., Liber, H. L., and Little, J. B., "Differential Effects of Radical Scavengers on X-Ray-Induced Mutation and Cytotoxicity in Human Cells," Radiation Research 109, 100-108 (1987).
Nygaard, O. F. and Simic, M. G., excerpt from Radioprotectors and Anticarcinogens, 73-85, (1983).
Grdina, D. J., Dale, P. and Weichselbaum, R., "Protection Against AZT-Induced Mutagenesis at the HGPRT Locus in a Human Cell Line by WR-151326," submitted for publication in Jan. 1991 to The International Journal of Radiation Oncology, Biology, Physics; presented at the Seventh International Conference on Chemical Modifiers for Cancer Treatment, Clearwater, Florida, Feb. 2-5, 1991. (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38; NIH/NCI grant CA-37435, U.S. Bioscience Inc. and the Center for Radiation Therapy.).
Milas, L., Hunter, N. and Stephens, L. C. and Peters, L. J., "Inhibition of Radiation Carcinogenesis in Mice by S-2(3-Aminopropylamino)-Methylphosphorothioic Acid," Cancer Research, vol. 44, 5567-5569, Dec. 1984. (Supported in part by grants CA-06294 and CA-16672, provided by the National Cancer Institute, Department of Health and Human Services.).
Grdina, D. J., Carnes, B. A., Grahn, D. and Sigdestad, C. P., "Protection Against Late Effects of Radiation by S-2-(3-Aminopropylamino)-Ethylphosphorothioic Acid," submitted to Cancer Research, vol. 51, 4125-4130 (1991). (Supported by the U.S. Department of Energy, under contract W-31-109-ENG-38; by NIH/NCI grant CA-37435 and by the Center for Radiation Therapy.).
Brown, J. M., "Sensitizers and Protectors and Radiotherapy," Cancer, 2222-22228, May 1 Supplement, 1985.
Constine, L. S., Zagars, G., Rubin, P. and Kligerman, M., "Protection by WR-2721 of Human Bone Marrow Function Following Irradiation," Int. J. Radiation Oncology Biol. Phys. vol. 12, 1505-1508, (1986).
Mahoney, F., "Summary Statement", Radiation Study Section, Feb. 1986.
Grdina, D. J., Nagy, B., Hill, C. K. and Sigdestad, C. P., "Protection Against Radiation-Induced Mutagenesis in V79 Cells by 2-[(Aminopropyl)amino] Ethanethiol Under Conditions of Acute Hypoxia," Radiation Research vol. 117, 251-258 (1989).
"Summary Statement," Radiation Study Section, Jan. 1989. Maisin, J. R., Mattelin, G. and Lambiet-Collier, M., Chemical Protection Against the Long-Term Effects of a Single Whole-Body Exposure of Mice to Ionizing Radiation, Radiation Research 71, 119-131 (1977).
Kataoka, Y., Basic, I., Perrin, J. and Grdina, D. J., "Anti-mutagenic effects of radioprotector WR-2721 against fission-spectrum-neutrons and Co-gamma rays in mice," Int. J. Radiation Oncology Biol Phys., vol. 61, 387-392 (1992). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38; NIH/NCI CA-37435 and the Center for Radiation Therapy in Chicago, Illinois).
Fry, R. J. M., "Radiation Carcinogenesis: Radioprotectors and Photosensitizers," Radioprotectors and Anticarcinogens, 417-436, (1983). (Supported by the Office of Health and Environmental Research, U.S. Department of Energy, under contract W-7405-eng-26 with the Union Carbide Corporation.).
Held, K. D., "Models for Thiol Protection of DNA in Cells," Pharmac. Ther., vol. 39, 123-131, (1988). (Supported in part by PHS grants CA42167 awarded by the National Cancer Institute, DHHS).
Grdina, D. J. and Sigdestad, C. P., "Radiation Protectors: The Unexpected Benefits," Drug Metabolism Reviews, 20(1), 13-42, (1989). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-103-ENG-38 and Public Health Service grant CA37435 awarded (D. J. G.) by the National Cancer Institute, Department of Human Services; and the U.S. Army Medical Research and Development Command, Fort Detrick, Maryland, under contracts DAMD17-86-C-6229 and DAMD17-C-7218 (C. P. S).
"1990 AACR Abstract Form" Temporary Abst. No. 247, of the paper Antimutagenic and Anticarcinogenic Effects of Aminothiols: Applications to the Clinic and Workplace. (Supported in part by U.S. Department of Energy contract W-31-109-ENG-38; NIH-NCI CA-37435 and the Center for Radiation Therapy in Chicago, Illinois).
"Abstracts," 3rd International Conference on Anticarcinogenesis & Radiation Protection, Oct. 15-21, 1989.
"Abstracts," twenty-eighth Plenary Meeting of the Committee on Space Research, Jun. 26-Jul. 6, 1990.
Kataoka, Y., Basic, I., Perrin, J. and Gridina, D. J., "Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neutrons .sup.60 Co gamma-rays in mice," Int. J. Radiat. Biol., (1992). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38; NIH/NCI CA-37435 and the Center for Radiation Therapy in Chicago, Illinois).
Zhang, X., Lai, P. and Taylor, Y., "Differential Radioprotection of Cultured Human Diploud Fibroblasts and Fibrosarcoma Cells by WR1065," International Journal of Radiation Oncology, Biology, Physics, vol. 21, Supp. 1 (1991).
Corn, B. W., Liber, H. L. and Little, J. B., "Differential Effects of Radical Scavengers on X-Ray-Induced Mutations and Cytotoxicity in Human Cells," Radiation Research 109, 100-108, (1987).
Grdina, D. J., Kataoka, Y., Basic, I. and Perrin, J., "The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes and administered prior to or following irradiation," Carcinogenesis, 13, 811-814 (1992). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38; NIH/NCI CA-37435 and the Center for Radiation Therapy in Chicago, Illinois).
Grdina, D. J., Carnes, B. A., Grahn, D. and Sigdestad, C. P., "Protection against Late Effects of Radiation by S-2-(3-Aminopropylamino)-ethylphosphorothioic Acid," Cancer Research vol. 51, 4125-4130, Aug. 15, 1991. Supported by the U.S. Department of Energy under contract W-31-109-ENG-38, by NIH/NCI grant CA-37435 and by the Center for Radiation Therapy.).
Carnes, B. A and Grdina, D. J., "In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis," Int. J. Radiat. Biol. 61, 567-576 (1992). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38; NIH/NCI CA-37435 and the Center for Radiation Therapy in Chicago, Illinois).
Grdina, D. J., Wright, B. J. and Carnes, B. A., "Protection by WR-151327 against Late-Effect Damage from Fission-Spectrum Neutrons," Radiation Research 127, (1991). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38, the Center of Radiation Therapy and NIH-NCI grant CA-37435.).
Kataoka, Y., Basic, I., Perrin, J. and Grdina, D. J., "Anti-mutagenic effects of radioprotector WR-2721 against fission-spectrum-neutrons and .sup.60 Co gamma-rays in mice," Int. J. Radiat. Biol., (1991). (Supported in part by the U.S. Department of Energy, Office of Health and Environmental Research, under contract W-31-109-ENG-38; NIH/NCI CA-37435 and the Center for Radiation Therapy in Chicago, Illinois).
Smoluk, G. D., Fahey, R. C., Calabro-Jones, P. M., Aguilera, J. A. and Ward, J. F., "Radioprotection of Cells in Culture by WR-2721 and Derivatives: Form the Drug Responsible for Protection," Cancer Research vol. 48, 3641-3647, Jul. 1, 1988. (Supported by grant CA-39582 from the National Cancer Institute).
Holwitt, E. A., Koda, E. and Swenberg, C. E., "Enhancement of Toposomerase I-Mediated Unwinding of
ARCH Development Corporation
Gerstl Robert
LandOfFree
Method for protection against genotoxic mutagenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for protection against genotoxic mutagenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for protection against genotoxic mutagenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2358753